HIV Screening in Pregnant Women: A Systematic Review of Cost-effectiveness Studies
Overview
Authors
Affiliations
Introduction: Vertical transmission represents the major route of HIV infection for children. However, the preventive interventions available are extremely effective. This review summarizes evidence regarding the cost-effectiveness of mother-to-child-transmission preventive screenings, to help policy makers in choosing the optimal antenatal screening strategy.
Methods: A systematic review following PRISMA guidelines was conducted, using 3 databases: PubMed, Scopus, and Cost-Effectiveness Analysis Registry. All articles regarding HIV screening to avoid vertical transmission were included.
Results: The review included 21 papers. Seven studies assessed the cost-effectiveness of universal antenatal screening during early gestation. Two papers considered the integration of HIV screening with other medical interventions. Eight works estimated the cost-effectiveness of HIV screening in late pregnancy. Finally, 4 papers considered the combination of multiple strategies. The selected papers focused on both developed and developing countries, with a different HIV prevalence. The characteristics and methodology of the studies were heterogeneous. However, all studies agreed about the main findings, outlining the cost-effectiveness of both universal antenatal screening and HIV rescreening in late pregnancy. Cost-effectiveness improved when HIV burden increased. The major findings were proved to be robust across various scenarios when tested in sensitivity analysis.
Conclusions: The review confirmed the cost-effectiveness not only of HIV universal antenatal screening but also of rescreening in late gestation in both developed and developing countries. Universal screening is cost-effective even in case of extremely low HIV prevalence. Therefore, to maximize screening, coverage appears as a worldwide priority. In certain settings, a targeted screening towards high-risk groups could be a valuable option.
Adawiyah R, Boettiger D, Applegate T, Probandari A, Marthias T, Guy R PLOS Glob Public Health. 2023; 2(8):e0000845.
PMID: 36962570 PMC: 10021386. DOI: 10.1371/journal.pgph.0000845.
Serag H, Clark I, Naig C, Lakey D, Tiruneh Y Int J Environ Res Public Health. 2023; 20(1).
PMID: 36612775 PMC: 9819288. DOI: 10.3390/ijerph20010457.
Approaches to improving the efficiency of HIV programme investments.
Shahid M, Bharali I, Hecht R, Yamey G BMJ Glob Health. 2022; 7(9).
PMID: 36113892 PMC: 9486198. DOI: 10.1136/bmjgh-2022-010127.
Licata F, Angelillo S, Nobile C, Di Gennaro G, Bianco A Front Med (Lausanne). 2022; 9:882125.
PMID: 35514754 PMC: 9063657. DOI: 10.3389/fmed.2022.882125.
Wheatley M, Knowlton G, Butler M, Enns E AIDS Behav. 2022; 26(7):2159-2168.
PMID: 35076798 PMC: 10478035. DOI: 10.1007/s10461-021-03561-w.